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The contents of hydroxyprolyP-bradykinin in high molecular mass (HMM) kininogens from human and animal plasmas 
were examined by reversed-phase HPLC following their proteolytic scission by bovine plasma kallikrein. The relative 
contents of hydroxyprolyP-bradykinin in kinins from HMM kininogens from pooled plasmas of human and monkey 
origin were 33 and 739&, respectively. On the other hand, hydroxyprolyP-bradykinin could not be detected in HMM 
kininogen preparations from bovine, rat, guinea pig, rabbit and mouse plasmas. Hydroxyproline in hydroxyprolyl-‘- 
bradykinin was assigned as rruns-4-hydroxyproline by comparison of the retention times on reversed-phase HPLC with 
isomers of hydroxyproline after derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole chloride. 
Kinin; Hydroxyproline; Kininogen; (Human, Monkey) 
1. INTRODUCTION 
In previous reports [ 1,2], we isolated Hyp 
analogues of BK, Hyp3-BK and Lys-Hyp3-BK, 
from ascites of cancer patients and normal human 
urine. In addition, Sasaguri et al. [3] recently 
isolated Lys-Hyp3-BK after the digestion of human 
plasma fraction with hog pancreatic kallikrein. 
The presence of the Hyp3-BK moiety in human 
HMM kininogens was confirmed very recently by 
two independent groups of investigators [4,5]. 
Their results suggest hat individual plasmas con- 
tain HMM kininogen with different contents of 
Hyp3-BK. It has been shown by McGee et al. [6] 
that the third proline residue in synthetic BK was 
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specifically hydroxylated by proline hydroxylase. 
Therefore, Hyp3-BK may be derived from BK in 
vivo by proline hydroxylase during or after biosyn- 
thesis of kininogen in liver, or other tissues like 
Hyp in collagen [7] and/or after liberation from 
kininogen by kallikreins. However, little is known 
of the in vivo mechanism of hydroxylation of BK 
in kininogens. To study the mechanism in vivo and 
in vitro, it will be helpful to use experimental 
animals in order to determine whether kininogens 
from animal plasmas contain Hyp3-BK. 
Here, we examined the Hyp3-BK content in 
HMM kininogens from animal plasmas in com- 
parison with human HMM kininogen. We also 
studied the stereospecificity of Hyp in Hyp3-BK 
obtained from human HMM kininogen. 
2. MATERIALS AND METHODS 
Synthetic BK, Hyp’-BK and trons-4-Hyp was purchased from 
the Peptide Institute (Minoh, Osaka). cis-4-Hyp was a product 
of Sigma (St. Louis, MO). truns-3-Hyp and cis-3-Hyp were 
kindly provided by Professor B. Witkop (NIH, Bethesda, MD) 
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through the courtesy of Dr F. Sakiyama (Institute for Protein 
Research, Osaka University, Osaka). Chelating Sepharose and 
Q-Sepharose (fast flow) were purchased from Pharmacia 
(Japan). Bovine plasma kallikrein with specific activity toward 
Z-Phe-Arg-methylcoumarin amide of 5.0 pmol aminomethyl 
coumarin per absorbance unit at 280 nm [8], bovine HMM 
kininogen [9] and rat HMM kininogen [lo] were isolated as 
reported previously. 
2.1. Purification of HMM kininogens from human, monkey, 
guinea pig, rabbit and mouse plasmas 
Citrated blood was collected from a rabbit and three guinea 
pigs, five normal volunteers, three monkeys and 45 mice. 15 or 
20 ml plasma was applied to a column (0.9 x 20 cm) of Q- 
Sepharose (fast flow) equilibrated with 0.02 M Tris-HCl, pH 
8.0, containing 0.05 M NaCl. Gradient elution was performed 
using an FPLC system (Pharmacia) with an NaCl gradient of 
0.05-0.5 M NaCl during a period of 120 min at a flow rate of 
1 ml/min. Kininogen activity was measured by cysteine pro- 
tease inhibitory activity using papain as in [ll]. HMM 
kininogen was eluted with 0.35-0.45 M NaCl and applied to a 
column (0.9 x 20 cm) of zinc-chelating Sepharose, equilibrated 
with 0.02 M Tris-HCl, pH 8.0, containing 0.05 M NaCl. HMM 
kininogen was eluted with 0.02 M Tris-HCl, pH 8.0, containing 
1 M NaCl and 50 mM EDTA. HMM kininogen preparations 
from each plasma showed a major band on SDS-PAGE in the 
presence of 2-mercaptoethanol with molecular masses of 104.8, 
106.1, 104.3, 108.6 and 97.6 kDa, for human, rabbit, mouse, 
monkey and guinea pig kininogens, respectively. Their proper- 
ties as HMM kininogen were also confirmed by correcting the 
prolonged clotting time of Fitzgerald trait plasma, and by kinin 
release following plasma kallikrein treatment. 
2.2. Kinin assay 
50-200 ~1 HMM kininogen solution in 0.02 M Tris-HCl, pH 
8.0, containing 0.15 M NaCl (A280 = 0.2-1.0) was mixed with 
10 ~1 bovine plasma kallikrein (Azso = 0.45) and the mixture 
was incubated for 20 min at 37°C. Quantitative analysis of 
kinin was performed by reversed-phase HPLC using a column 
(4.6 mm x 25 cm) of TSK gel ODS-12OA (Toso) with isocratic 
elution using 17% acetonitrile as reported [l]. The area of pep- 
tides corresponding to Hyp’-BK and BK was calculated on a 
Chromatocorder 11 (System Instruments, Tokyo) and con- 
verted to the amounts of kinin using a standard curve that was 
constructed using synthetic kinins. 
2.3. Separation of isomers of Hyp 
Isomers of Hyp were separated after derivatization with 
NBD-Cl according to Lindblad and Diegelmann [12]. NBD- 
Hyp was subjected to reversed-phase HPLC using a column 
(4.6 mm x 25 cm) of TSK gel ODS-120A at room temperature 
and eluted by increasing the concentration of methanol in 1% 
acetic acid, pH 2.73, at a flow rate of 1 ml/min and with detec- 
tion at 495 nm. 
2.4. Amino acid sequence analysis 
The amino acid sequence was analysed using a model 470A 
gas-phase protein sequencer equipped with a 12OA PTH 
analyzer on an on-line system (Applied Biosystems, Foster City, 
CA). PTH-Hyp was assigned and quantitated by its 
characteristic two-peak profile as in [l]. 
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3. RESULTS 
The amounts of kinins liberated from HMM 
kininogens from human, monkey, bovine, rat, 
mouse, rabbit and guinea pig plasmas were 
measured by reversed-phase HPLC after incuba- 
tion with bovine plasma kallikrein as described in 
section 2. As shown in fig.lB,E, two peptide peaks 
were detected on human and monkey HMM 
kininogens from pooled plasmas, which corres- 
pond to Hyp3-BK and BK. The relative content of 
Hyp3-BK in total kinin was calculated to be 33 and 
73% ip human and monkey HMM kininogens, 
respectively. The Hyp3-BK content in human 
HMM kininogens from five individuals ranged 
from 14 to 64%. On the other hand, a peptide peak 
that corresponds to Hyp3-BK was not detected 
from bovine, rat, guinea pig and rabbit HMM 
kininogen preparations (fig. lC,D,F,G). Two pep- 
tide peaks were detected in mouse HMM 
kininogen, one of which corresponded to BK, and 
another that did not correspond to Hyp3-BK 
(fig.lH). When the digest of mouse HMM 
kininogen with bovine plasma kallikrein was sub- 
jected to preparative HPLC using a gradient of 
acetonitrile, neither peptide was separated. Amino 
acid sequence analysis of the mixture indicated 
that a major component in the mixture is BK, 
which includes a minor sequence of Asp-X-Gly- 
Leu-X-X-Gly-Gln-Gln-Lys-. From these results, 
we conclude that mouse HMM kininogen does not 
contain a Hyp3-BK moiety. The amino acid se- 
quences of Hyp3-BK from human and monkey 
HMM kininogens were confirmed from their 
amino acid sequence analyses (fig.2) and amino 
acid composition (not shown). 
These results indicate that HMM kininogens 
from human and monkey plasmas contain 
Hyp3-BK, but HMM kininogens from bovine, rat, 
rabbit, guinea pig and mouse plasmas do not. 
Although truns-4-Hyp is most abundant in col- 
lagen, four isomers of Hyp are known to be pre- 
sent in nature [13] depending on the stereospe- 
cificity of the hydroxyl radical. The stereospecifici- 
ty of Hyp from human HMM kininogen was ex- 
amined by comparison with the synthetic isomers, 
tram-4-Hyp, cis-4-Hyp, tram-3-Hyp and cis-3- 
Hyp. A 6 N HCI hydrolysate of Hyp3-BK and the 
synthetic isomers were incubated with NBD-Cl. 
NBD-Hyp derivatives were separated by reversed- 
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Fig.1. Quantitative analyses of Hyp’-BK and BK in HMM 
kininogen by reversed-phase HPLC. HMM kininogens from 
human pooled plasma (B), rat plasma (C), bovine plasma (D), 
monkey plasma (E), guinea pig plasma (F), rabbit plasma (G) 
and mouse plasma (H) were incubated with bovine plasma 
kallikrein and the kinins liberated were separated on a column 
of TSK gel ODS-12OA with isocratic elution with 17% 
acetonitrile. The amounts of kinin were calculated as described 
in section 2. (A) Hyp3-BK (a) and BK (b). 
human 4rg Pro Hyp Gly Phe Ser Pro Phe Arg 
777-7-777 
48 139 43 126 101 29 64 59 11 
monkey Arg Pro Hyp Gly Phe Ser Pro Phe Arg 
-7-777’7-3 
137 542 185 383 475 107 310 281 24 
Fig.2. Amino acid sequence of Hyp’-BKs from human and 
monkey HMM kininogens. Each value under the amino acid 
residue represents pmol PTH-amino acids. 
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Fig.3. Separation of isomers of Hyp by reversed-phase HPLC. 
Peptides were hydrolyzed with 6 N HCI for 20 h at 110°C. The 
hydrolysates and synthetic isomers of Hyp and proline were 
derivatized with NBD-Cl and subjected to reversed-phase 
HPLC as described in section 2. (A) Standard Hyps and 
proline: (a) truns-3-Hyp, (b) trans-4-Hyp, (c) cis-3-Hyp, (d) 
cis-4-Hyp, (e) proline. (B) Hydrolysate of Hyp’-BK from 
human HMM kininogen (0.6 nmol). (C) B and truns-3-Hyp. 
(D) Hydrolysate of synthetic Hyp’-BK (0.13 nmol). 
phase HPLC as described in section 2. As shown 
in fig.3A, truns and cis isomers of Hyp and proline 
were clearly separated under the conditions used. 
Although the retention times of truns-3-Hyp and 
trans-4-Hyp were very close, they were distinguish- 
able. On the other hand, cis-3-Hyp and cis-4-Hyp 
were virtually indistinguishable. The retention time 
of Hyp from Hyp3-BK in human HMM kininogen 
and from synthetic Hyp3-BK was identical with 
that of trans-4-Hyp (fig.3B,D). The result was con- 
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firmed by the addition of truns-3-Hyp to the 
hydrolysate of Hyp3-BK from human HMM 
kininogen (fig.3C). 
4. DISCUSSION 
The present paper demonstrates that Hyp in 
Hyp3-BK is trans-4-Hyp, and therefore that it was 
derived from the action of proline-4-hydroxylase 
on kininogen. This article also demonstrates that 
HMM kininogen from pooled monkey plasmas 
contained higher amounts of Hyp3-BK than 
human HMM kininogen. Maier et al. [5] isolated 
Lys-Hyp3-BK from human individual HMM 
kininogens after incubation with human urinary 
kallikrein and estimated the content to be 30-59% 
from the biological activity of the kinin. Our 
results confirm that human HMM kininogen from 
individual plasma contains variable amounts of 
Hyp3-BK. It is well known that proline-4-hydroxy- 
lase is essential for the hydroxylation of proline in 
procollagen. In particular, the enzymes from 
human and rat have been well characterized [7]. 
Hence, it is reasonable to speculate that the BK 
moiety in HMM kininogen is hydroxylated via the 
same mechanism as that for collagen. 
On the other hand, it is interesting that HMM 
kininogens from bovine, rat, guinea pig, rabbit 
and mouse plasmas do not contain Hyp3-BK. We 
isolated HMM kininogens from pooled plasmas of 
ox, rat, guinea pig and mice, except rabbit. It may 
be premature at this point to conclude that only 
primate HMM kininogens contain Hyp3-BK, as 
further investigation should be made on other 
animals. However, our data pose the following 
questions concerning the mechanism of hydroxyla- 
tion of the BK moiety in HMM kininogen: (i) is 
HMM kininogen hydroxylated by proline4-hy- 
droxylase located on the cisternae of rough endo- 
plastic reticulum in the liver similarly to the 
hydroxylation of procollagen, or by an enzyme in 
a different organ? (ii) if we assume the same 
mechanism in human, monkey and other animals, 
why then do HMM kininogens from non-primates 
not contain Hyp3-BK? and (iii) do our data really 
indicate that experimental animals except monkey 
cannot be used for studies concerning the 
mechanism of proline hydroxylation in kininogen? 
4 
In order to resolve these questions, it may be essen- 
tial to determine whether HMM kininogen is 
hydroxylated in vitro by proline hydroxylase, and 
whether HMM kininogen with Hyp3-BK in animal 
plasma increases in experimentally induced liver 
fibrosis and other diseases in which collagen pro- 
line hydroxylase activity increases [14,151. 
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